Abstract
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus affecting both children and adults, with debilitating and progressive symptoms. EoE has shown an explosive epidemiological rise in the past few decades. Many patients experience a poor level of disease control despite maximal use of available guideline-based therapies, which seriously hampers their quality of life. Diet restrictions and systemic and topical corticosteroids are the current mainstays of EoE therapy, but are associated with significant efficacy, treatment compliance, and safety issues such as oral or esophageal candidiasis, growth retardation, osteopenia, osteoporosis, glucose intolerance, and cataract formation. As EoE is a chronic inflammatory disease, immune cells and cytokines are responsible for the inflammatory response and symptoms. Monoclonal antibodies specifically targeting these pathophysiologic effectors offer more potent relief of histologic and clinical disease features while keeping off-target adverse effects to a minimum. Herein, we have reviewed the current evidence regarding efficacy and safety of monoclonal antibodies including mepolizumab (anti-IL-5), reslizumab (anti-IL-5), QAX576 (anti-IL-13), omalizumab (anti-immunoglobulin-E), and infliximab (anti-TNF-α) in treatment of EoE. Our review indicates that although the use of monoclonal antibodies for EoE treatment is safe with limited and reversible adverse events, however, it is not yet possible to reach a final verdict on the efficacy of mAbs in EoE. Future well-designed studies are needed to clarify the exact role of mAbs in EoE.
Similar content being viewed by others
Abbreviations
- EoE:
-
Eosinophilic esophagitis
- IL:
-
Interleukin
- US:
-
United States
- Th1/2:
-
T helper type 1/2
- TGF:
-
Transforming growth factor
- FGF:
-
Fibroblast growth factor
- mg:
-
Milligrams
- kg:
-
Kilograms
- hpf:
-
High-power field
- CCR3:
-
c-c chemokine receptor type 3
- FIP1L1:
-
Factor interacting with PAPOLA and CPSF1
- PDGFRA:
-
Platelet-derived growth factor receptor alpha
- FDA:
-
Food and Drug Administration
- CI:
-
Confidence interval
- MDQ:
-
Mayo Dysphagia Questionnaire
- CXCL:
-
Chemokine (C-X-C motif) ligand
- DHRS9:
-
Dehydrogenase/reductase SDR family member 9
- CPA3:
-
Carboxypeptidase A3
- Ig:
-
Immunoglobulin
- EGID:
-
Eosinophil-associated gastrointestinal disorder
- TNF:
-
Tumor necrosis factor
- IFN:
-
Interferon
- mAb:
-
Monoclonal antibody
References
Straumann A (2011) The natural history and complications of eosinophilic esophagitis. Thorac Surg Clin 21(4):575–587. https://doi.org/10.1016/j.thorsurg.2011.09.004
Walsh GM (2010) Reslizumab for pediatric eosinophilic esophagitis. Immunotherapy 2(4):461–465. https://doi.org/10.2217/imt.10.41
Rothenberg ME (2004) Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 113(1):11–28; quiz 29. https://doi.org/10.1016/j.jaci.2003.10.047
Straumann A (2008) The natural history and complications of eosinophilic esophagitis. Gastrointest Endosc Clin N Am 18(1):99–118; ix. https://doi.org/10.1016/j.giec.2007.09.009
Straumann A, Schoepfer AM (2012) Therapeutic concepts in adult and paediatric eosinophilic oesophagitis. Nat Rev Gastroenterol Hepatol 9(12):697–704. https://doi.org/10.1038/nrgastro.2012.182
Straumann A, Beglinger C (2006) Eosinophilic esophagitis: the endoscopist’s enigma. Gastrointest Endosc 63(1):13–15. https://doi.org/10.1016/j.gie.2005.09.010
Remedios M, Campbell C, Jones DM, Kerlin P (2006) Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 63(1):3–12. https://doi.org/10.1016/j.gie.2005.07.049
Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, Straumann A, Rothenberg ME, First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees (2007) Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 133(4):1342–1363. https://doi.org/10.1053/j.gastro.2007.08.017
Dougherty T Jr, Stephen S, Borum ML, Doman DB (2014) Emerging therapeutic options for eosinophilic esophagitis. Gastroenterol Hepatol (N Y) 10(2):106–116
Liacouras CA, Furuta GT, Hirano I et al (2011) Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 128(1):3–20.e6 quiz 21–2
Aceves SS, Newbury RO, Dohil R, Schwimmer J, Bastian JF (2007) Distinguishing eosinophilic esophagitis in pediatric patients: clinical, endoscopic, and histologic features of an emerging disorder. J Clin Gastroenterol 41(3):252–256. https://doi.org/10.1097/01.mcg.0000212639.52359.f1
DeBrosse CW, Collins MH, Buckmeier Butz BK, Allen CL, King EC, Assa’ad AH, Abonia JP, Putnam PE, Rothenberg ME, Franciosi JP (2010) Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982–1999. J Allergy Clin Immunol 126(1):112–119. https://doi.org/10.1016/j.jaci.2010.05.027
Hruz P, Straumann A, Bussmann C et al (2011) Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland. J Allergy Clin Immunol 128(6):1349–1350.e5
Soon IS, Butzner JD, Kaplan GG, de Bruyn JC (2013) Incidence and prevalence of eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr 57(1):72–80. https://doi.org/10.1097/MPG.0b013e318291fee2
Veerappan GR, Perry JL, Duncan TJ et al (2009) Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. Clin Gastroenterol Hepatol 7(4):420–426 426.e1–2
Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman MD (2014) Prevalence of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol 12(4):589–96.e1
Dellon ES (2014) Epidemiology of eosinophilic esophagitis. Gastroenterol Clin N Am 43(2):201–218. https://doi.org/10.1016/j.gtc.2014.02.002
Lewis CJ, Lamb CA, Kanakala V, Pritchard S, Armstrong GR, Attwood SEA (2009) Is the etiology of eosinophilic esophagitis in adults a response to allergy or reflux injury? Study of cellular proliferation markers. Dis Esophagus 22(3):249–255. https://doi.org/10.1111/j.1442-2050.2008.00896.x
Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J, Dias JA (2011) Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 170(11):1471–1474. https://doi.org/10.1007/s00431-011-1540-4
Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, Melin–Aldana H, Li BUK (2006) Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 4(9):1097–1102. https://doi.org/10.1016/j.cgh.2006.05.026
Gonsalves N, Yang GY, Doerfler B et al (2012) Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 142(7):1451–9.e1 quiz e14–5
Liacouras CA, Wenner WJ, Brown K, Ruchelli E (1998) Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 26(4):380–385. https://doi.org/10.1097/00005176-199804000-00004
Schaefer ET, Fitzgerald JF, Molleston JP, Croffie JM, Pfefferkorn MD, Corkins MR, Lim JD, Steiner SJ, Gupta SK (2008) Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 6(2):165–173. https://doi.org/10.1016/j.cgh.2007.11.008
Faubion WA Jr, Perrault J, Burgart LJ et al (1998) Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr 27(1):90–93. https://doi.org/10.1097/00005176-199807000-00016
Arora AS, Perrault J, Smyrk TC (2003) Topical corticosteroid treatment of dysphagia due to eosinophilic esophagitis in adults. Mayo Clin Proc 78(7):830–835. https://doi.org/10.4065/78.7.830
Lucendo AJ, Pascual-Turrion JM, Navarro M et al (2007) Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: a case series. Endoscopy 39(9):765–771. https://doi.org/10.1055/s-2007-966738
Dohil R, Newbury R, Fox L, Bastian J, Aceves S (2010) Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 139(2):418–429. https://doi.org/10.1053/j.gastro.2010.05.001
Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, Akers R, Cohen MB, Collins MH, Assa’ad AH, Aceves SS, Putnam PE, Rothenberg ME (2006) A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 131(5):1381–1391. https://doi.org/10.1053/j.gastro.2006.08.033
Liacouras CA, Spergel JM, Ruchelli E, Verma R, Mascarenhas M, Semeao E, Flick J, Kelly J, Brown–Whitehorn T, Mamula P, Markowitz JE (2005) Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 3(12):1198–1206. https://doi.org/10.1016/S1542-3565(05)00885-2
Spergel JM, Andrews T, Brown-Whitehorn TF, Beausoleil JL, Liacouras CA (2005) Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol 95(4):336–343. https://doi.org/10.1016/S1081-1206(10)61151-9
Butz BK, Wen T, Gleich GJ et al (2014) Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology 147(2):324–33.e5
Bochner BS, Book W, Busse WW, Butterfield J, Furuta GT, Gleich GJ, Klion AD, Lee JJ, Leiferman KM, Minnicozzi M, Moqbel R, Rothenberg ME, Schwartz LB, Simon HU, Wechsler ME, Weller PF (2012) Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). J Allergy Clin Immunol 130(3):587–596. https://doi.org/10.1016/j.jaci.2012.07.024
Straumann A, Conus S, Degen L et al (2011) Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 9(5):400–9.e1
Peterson KA, Thomas KL, Hilden K, Emerson LL, Wills JC, Fang JC (2010) Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 55(5):1313–1319. https://doi.org/10.1007/s10620-009-0859-4
Runge TM, Dellon ES (2015) Do we know what causes eosinophilic esophagitis? A mechanistic update. Curr Gastroenterol Rep 17(9):33. https://doi.org/10.1007/s11894-015-0458-9
Lucendo AJ (2014) Cellular and molecular immunological mechanisms in eosinophilic esophagitis: an updated overview of their clinical implications. Expert Rev Gastroenterol Hepatol 8(6):669–685. https://doi.org/10.1586/17474124.2014.909727
Hirano I, Aceves SS (2014) Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis. Gastroenterol Clin N Am 43(2):297–316. https://doi.org/10.1016/j.gtc.2014.02.015
Khorasanizadeh M, Eskian M, Assa’ad AH, Camargo CA Jr, Rezaei N (2016) Efficacy and safety of benralizumab, a monoclonal antibody against IL-5Ralpha, in uncontrolled eosinophilic asthma. Int Rev Immunol 35(4):294–311. https://doi.org/10.3109/08830185.2015.1128901
Grainge CL, Maltby S, Gibson PG, Wark PA, McDonald VM (2016) Targeted therapeutics for severe refractory asthma: monoclonal antibodies. Expert Rev Clin Pharmacol 9(7):927–941. https://doi.org/10.1586/17512433.2016.1172208
Khorasanizadeh M, Eskian M, Gelfand EW, Rezaei N (2017) Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacol Ther 174:112–126. https://doi.org/10.1016/j.pharmthera.2017.02.024
Khorasanizadeh M, Eskian M, Rezaei N (2017) Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Acta Med Iran 55(5):352–353
Gleich GJ (2000) Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105(4):651–663. https://doi.org/10.1067/mai.2000.105712
Furuta GT, Atkins FD, Lee NA, Lee JJ (2014) Changing roles of eosinophils in health and disease. Ann Allergy Asthma Immunol 113(1):3–8. https://doi.org/10.1016/j.anai.2014.04.002
Kay, A.B. and A.D. Klion, Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol Allergy Clin N Am, 2004. 24(4): p. 645–666, vii, DOI: https://doi.org/10.1016/j.iac.2004.06.007
Otani IM, Anilkumar AA, Newbury RO, Bhagat M, Beppu LY, Dohil R, Broide DH, Aceves SS (2013) Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol 131(6):1576–1582. https://doi.org/10.1016/j.jaci.2013.02.042
Mishra A (2009) Mechanism of eosinophilic esophagitis. Immunol Allergy Clin N Am 29(1):29–40, viii. https://doi.org/10.1016/j.iac.2008.09.010
Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa’ad AH, Rothenberg ME (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113(1):115–119. https://doi.org/10.1016/j.jaci.2003.10.049
Mavi P, Rajavelu P, Rayapudi M, Paul RJ, Mishra A (2012) Esophageal functional impairments in experimental eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol 302(11):G1347–G1355. https://doi.org/10.1152/ajpgi.00013.2012
Mishra A, Wang M, Pemmaraju VR, Collins MH, Fulkerson PC, Abonia JP, Blanchard C, Putnam PE, Rothenberg ME (2008) Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology 134(1):204–214. https://doi.org/10.1053/j.gastro.2007.10.002
Mishra A, Hogan SP, Brandt EB, Rothenberg ME (2002) IL-5 promotes eosinophil trafficking to the esophagus. J Immunol 168(5):2464–2469. https://doi.org/10.4049/jimmunol.168.5.2464
Akei HS, Mishra A, Blanchard C, Rothenberg ME (2005) Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice. Gastroenterology 129(3):985–994. https://doi.org/10.1053/j.gastro.2005.06.027
Mishra A, Hogan SP, Brandt EB, Rothenberg ME (2001) An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest 107(1):83–90. https://doi.org/10.1172/JCI10224
Bullock JZ, Villanueva JM, Blanchard C, Filipovich AH, Putnam PE, Collins MH, Risma KA, Akers RM, Kirby CL, Buckmeier BK, Assa’ad AH, Hogan SP, Rothenberg ME (2007) Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 45(1):22–31. https://doi.org/10.1097/MPG.0b013e318043c097
Blanchard C, Stucke EM, Rodriguez-Jimenez B et al (2011) A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol 127(1):208–217 217.e1–7
Corren J (2012) Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med 13(71):305–312
Stein ML, Collins MH, Villanueva JM et al (2006) Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118(6):1312–1319. https://doi.org/10.1016/j.jaci.2006.09.007
Assa’ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, Perschy TL, Jurgensen CH, Ortega HG, Aceves SS (2011) An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141(5):1593–1604. https://doi.org/10.1053/j.gastro.2011.07.044
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360(10):973–984. https://doi.org/10.1056/NEJMoa0808991
Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215–1228. https://doi.org/10.1056/NEJMoa070812
Conus S, Straumann A, Simon HU (2009) Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis. J Allergy Clin Immunol 123(1):269; author reply 269–70. https://doi.org/10.1016/j.jaci.2008.09.031
Conus S, Straumann A, Bettler E, Simon HU (2010) Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis. J Allergy Clin Immunol 126(1):175–177. https://doi.org/10.1016/j.jaci.2010.04.029
Stein ML, Villanueva JM, Buckmeier BK et al (2008) Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 121(6):1473–1483 1483 e1–4
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NCP, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201–1214. https://doi.org/10.1056/NEJMoa025217
Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59(1):21–30. https://doi.org/10.1136/gut.2009.178558
Spergel JM, Rothenberg ME, Collins MH et al (2012) Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 129(2):456–463 463.e1–3
Markham A (2016) Reslizumab: First Global Approval. Drugs 76(8):907–911. https://doi.org/10.1007/s40265-016-0583-2
Sherrill JD, Kc K, Wu D et al (2014) Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol 7(3):718–729. https://doi.org/10.1038/mi.2013.90
Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, Collins MH, Putnam PE, Wells SI, Rothenberg ME (2007) IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol 120(6):1292–1300. https://doi.org/10.1016/j.jaci.2007.10.024
Uhm TG, Kim BS, Chung IY (2012) Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res 4(2):68–79. https://doi.org/10.4168/aair.2012.4.2.68
Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A, Jones I, Arm JP, Strieter RM, Sabo R, Gunawardena KA (2015) Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 135(2):500–507. https://doi.org/10.1016/j.jaci.2014.07.049
Abonia JP, Blanchard C, Butz BB, Rainey HF, Collins MH, Stringer K, Putnam PE, Rothenberg ME (2010) Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 126(1):140–149. https://doi.org/10.1016/j.jaci.2010.04.009
Trivedy P, Teitelbaum JE (2015) Eosinophilic esophagitis in children. Paediatr Drugs 17(3):227–237. https://doi.org/10.1007/s40272-015-0126-4
Normansell R, Walker S, Milan SJ, Walters EH, Nair P (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev (1):Cd003559
Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, Marseglia GL (2014) Omalizumab in children. Paediatr Drugs 16(6):491–502. https://doi.org/10.1007/s40272-014-0107-z
Arasi S, Costa S, Magazzu G et al (2016) Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis. Ital J Pediatr 42(1):32. https://doi.org/10.1186/s13052-016-0243-x
Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, Lowichik A, Chen X, Emerson L, Cox K, O’Gorman MA, Peterson KA (2014) Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology 147(3):602–609. https://doi.org/10.1053/j.gastro.2014.05.036
Loizou D, Enav B, Komlodi-Pasztor E, Hider P, Kim-Chang J, Noonan L, Taber T, Kaushal S, Limgala R, Brown M, Gupta R, Balba N, Goker-Alpan O, Khojah A, Alpan O (2015) A pilot study of omalizumab in eosinophilic esophagitis. PLoS One 10(3):e0113483. https://doi.org/10.1371/journal.pone.0113483
Foroughi S, Foster B, Kim N et al (2007) Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 120(3):594–601. https://doi.org/10.1016/j.jaci.2007.06.015
Gupta SK, Fitzgerald JF, Kondratyuk T, HogenEsch H (2006) Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 42(1):22–26. https://doi.org/10.1097/01.mpg.0000188740.38757.d2
Muir AB, Dods K, Noah Y, Toltzis S, Chandramouleeswaran PM, Lee A, Benitez A, Bedenbaugh A, Falk GW, Wells RG, Nakagawa H, Wang ML (2015) Esophageal epithelial cells acquire functional characteristics of activated myofibroblasts after undergoing an epithelial to mesenchymal transition. Exp Cell Res 330(1):102–110. https://doi.org/10.1016/j.yexcr.2014.08.026
Straumann A, Bauer M, Fischer B, Blaser K, Simon HU (2001) Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 108(6):954–961. https://doi.org/10.1067/mai.2001.119917
Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, Jameson SC, Kirby C, Konikoff MR, Collins MH, Cohen MB, Akers R, Hogan SP, Assa’ad AH, Putnam PE, Aronow BJ, Rothenberg ME (2006) Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 116(2):536–547. https://doi.org/10.1172/JCI26679
Straumann A, Bussmann C, Conus S, Beglinger C, Simon HU (2008) Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 122(2):425–427. https://doi.org/10.1016/j.jaci.2008.06.012
Noel RJ, Putnam PE, Collins MH, Assa’ad AH, Guajardo JR, Jameson SC, Rothenberg ME (2004) Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol 2(7):568–575. https://doi.org/10.1016/S1542-3565(04)00240-X
Noel RJ, Rothenberg ME (2005) Eosinophilic esophagitis. Curr Opin Pediatr 17(6):690–694. https://doi.org/10.1097/01.mop.0000184291.34654.be
Raheem M, Leach ST, Day AS, Lemberg DA (2014) The pathophysiology of eosinophilic esophagitis. Front Pediatr 2:41
Antico A, Fante R (2014) Esophageal hypereosinophilia induced by grass sublingual immunotherapy. J Allergy Clin Immunol 133(5):1482–1484. https://doi.org/10.1016/j.jaci.2014.01.030
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
No human or animals participants were included in this study.
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Eskian, M., Khorasanizadeh, M., Assa’ad, A.H. et al. Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis. Clinic Rev Allerg Immunol 55, 88–98 (2018). https://doi.org/10.1007/s12016-017-8659-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-017-8659-7